Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant interferon treatment for melanoma

S S Agarwala1, J M Kirkwood

  • 1University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania, USA.

Hematology/Oncology Clinics of North America
|October 6, 1998
PubMed
Summary

Recombinant interferon alfa-2b significantly improves survival and relapse-free intervals for high-risk melanoma patients. Despite toxicity, cost-efficacy analyses support its use, particularly for node-positive individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-year survival with tebentafusp in metastatic uveal melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis.

Immuno-oncology technology·2025
Same author

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Schilling et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Targeting the MAPK pathway in advanced BRAF wild-type melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey.

The British journal of dermatology·2018

Area of Science:

  • Oncology
  • Immunotherapy
  • Melanoma Research

Background:

  • Adjuvant therapy for melanoma remains a critical area of research.
  • Recombinant interferon alfa-2b (IFN-α2b) has shown promise in improving patient outcomes.
  • Optimizing dosage and duration of IFN-α2b therapy is essential for maximizing benefits.

Purpose of the Study:

  • To evaluate the survival and relapse-free interval benefits of adjuvant recombinant IFN-α2b in melanoma patients.
  • To assess the quality-of-life and cost-effectiveness of IFN-α2b therapy.
  • To explore the role of abbreviated high-dose IFN-α regimens in stage IIA melanoma.

Main Methods:

  • Analysis of data from the ECOG (E1684) trial.
  • Retrospective quality-of-life assessments using Q-TWiST methods.
  • Cost-efficacy analyses to determine the utility of the intervention.

Main Results:

  • Maximally tolerable dosages of intravenous and subcutaneous IFN-α2b demonstrated significant survival and relapse-free interval benefits.
  • Cost-efficacy and quality-of-life analyses supported the utility of IFN-α2b, especially for node-positive melanoma patients.
  • Lower IFN dosages showed transient benefits, but these were not sustained with longer follow-up.

Conclusions:

  • Adjuvant IFN-α2b therapy offers significant benefits for high-risk melanoma patients, particularly those who are node-positive.
  • Despite toxicity, the intervention is cost-effective and improves quality-of-life.
  • Ongoing research focuses on refining IFN-α dosage, duration, and comparing it with active specific immunotherapy, including potential abbreviated regimens for stage IIA melanoma.

Related Experiment Videos